Pressure Biosciences, Inc. (OTCQB: PBIO)Revenue Continues to Increase

13:41
 
Share
 

Manage episode 206611071 series 1508950
By InvestorTownHall. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Pressure Biosciences, Inc. (OTCQB: PBIO) CEO Ric Schumacher was on Investor Town Hall Show discussing the latest company developments. Operational & Technical Highlights: FY2017 A significant software upgrade for our flagship Barocycler 2320EXTREME has brought our next-generation PCT-based instrument to GMP and GLP compliance, which in turn should open many new doors in the biopharmaceutical manufacturing and drug discovery & development areas of the very large life sciences field. The acquisition of all assets of BaroFold Corporation combines BaroFold's patented high-pressure protein refolding technology (PreEMT) with PBI's leadership in high-pressure instrumentation and worldwide market access, which will allow PBI entry into the Biologics Contract Research Services Sector. Professor Tiannan Guo's laboratory at the world famous Westlake Institute for Advanced Study was named PBI's first Center of Excellence in China, which we believe should support an aggressive marketing and sales strategy in China, which in turn could drive significant expansion in China and the rest of Asia. We believe our strategic collaboration with Phasex Corporation will allow us to address broad markets for stable, water-soluble nanoemulsions. We expect the combination of our recently patented Ultra Shear Technology (UST) with Phasex's Supercritical Fluid processing methods will enable development of stable, water-soluble nanoemulsions, including CBD-enriched plant oil. We were issued the first two patents on our widely-applicable, high pressure-based Ultra Shear Technology. We believe that UST can be used to create or improve a broad range of medical, consumer, and industrial products through the preparation of high-quality nanoemulsions and "clean label" food. Our recently-released, next-generation Barocycler 2320EXTREME instrument was named a finalist in the prestigious 2017 R&D 100 Awards. Known as the "Oscars of Innovation", the R&D 100 Awards recognize the top 100 revolutionary technologies of the past year. Professor Ruedi Aebersold, a worldwide expert in proteomics and one of PBI's most well-known clients, received the prestigious Karger Medal for significant contributions to the development of new bioanalytical methods. In his acceptance speech, he discussed the importance of sample preparation and mentioned his use of the PCT Platform. Joseph L. Damasio, Jr. joined the Company as our full-time Chief Financial Officer and Vice President of Finance. Our Barocycler 2320EXTREME was named "Best New Instrument for Sample Preparation 2017" by Corporate America News ("Corp America") as part of the publication's 2017 North American Excellence Awards. We achieved CE Marking for our flagship instrument, the next-generation Barocycler 2320EXTREME. CE Marking permits PBI to begin sales of the 2320EXT to all 31 countries of the European Economic Area. For more information visit: www.PressureBioSciences.com Disclaimer: Investor Town Hall, LLC is a paid advertiser for producing video content and technical/creative multimedia services. Investor Town Hall, LLC is not a broker-dealer, registered investment adviser, financial analyst, investment broker, financial adviser, or any sort of professional that would be deemed as an individual someone would rely upon for investment advice. Although information has been obtained from sources which we believe to be reliable, we do not warrant that it is accurate or complete and any such information may be subject to change at any time. It is recommended to seek advice from a licensed financial advisor before making any investment decisions. Investor Town Hall, LLC hall shall not be held liable for any damages or losses from information disseminated within the advertisement.

61 episodes